ARM & ISCT's Impact On CGT

Bone Therapeutics has received regulatory approvals for its clinical trial applications for the next studies of both its lead candidates. In the full-length video, Miguel Forte, CEO of Bone Therapeutics and I talk about the significance of these two studies as well as COVID-19’s impact on the cell and gene sector.

Here, Forte answers my question about the impact that both ARM and ISCT have on the cell and gene sector and what the organizations are working on now.

Embed